Meeting
2018 Gastrointestinal Cancers Symposium
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
Authors
Jordi Bruix
BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, CIBEREHD, IDIBAPS, Barcelona, Spain
Jordi Bruix , Philippe Merle , Alessandro Granito , Yi-Hsiang Huang , Gyorgy Bodoky , Osamu Yokosuka , Olivier Rosmorduc , Valeriy Vladimirovich Breder , René Gerolami , Gianluca Masi , Paul J. Ross , Shukui Qin , Tianqiang Song , Jean-Pierre Bronowicki , Isabelle Ollivier-Hourmand , Masatoshi Kudo , Lei Xu , Annette Baumhauer , Gerold Meinhardt , Guohong Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01774344
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 412)
DOI
10.1200/JCO.2018.36.4_suppl.412
Abstract #
412
Poster Bd #
K5
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.
First Author: Michael Teufel
Poster
2023 ASCO Annual Meeting
The efficacy of hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: A phase 3 randomized self-controlled study, J-SUPPORT 1701 APRON trial.
First Author: Atsuo Takashima
Poster
2019 Gastrointestinal Cancers Symposium
A nationwide multicenter study in patients with unresectable hepatocellular carcinoma treated with lenvatinib in real world practice in Japan.
First Author: Kaoru Tsuchiya
Poster
2017 Gastrointestinal Cancers Symposium
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.
First Author: Jordi Bruix